Current and emerging pharmacological treatments for respiratory syncytial virus infection in high-risk infants-Reference-Cited by-同舟云学术

Current and emerging pharmacological treatments for respiratory syncytial virus infection in high-risk infants

Published:2023-05-16 Issue:10 Volume:24 Page:1143-1158
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Soto Jorge A.¹²^ORCID,Loaiza Ricardo A.¹^ORCID,Echeverría Sebastián²,Ramírez Robinson A.¹,Kalergis Alexis M.¹³^ORCID

Affiliation:

1. Millennium Institute of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile

2. Departamento de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile

3. Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2213433

Reference156 articles.

1. Taxonomy of the order Mononegavirales: update 2016

2. Human respiratory syncytial virus and hospitalization in young children in Italy

3. A systematic review on global RSV genetic data: Identification of knowledge gaps

4. Variation in the seasonality of the respiratory syncytial virus during the COVID-19 pandemic

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A molecular perspective for the development of antibodies against the human respiratory syncytial virus;Antiviral Research;2024-02